Evidence map›Paper›PMID 34893824›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV).

Khadija Khan, Gila Lustig, Mallory Bernstein, Derseree Archary, Sandile Cele, Farina Karim, Muneerah Smith, Yashica Ganga, Zesuliwe Jule, Kajal Reedoy and 15 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. The immune response to SARS-CoV-2 in people with HIV.Cellular & molecular immunology · 2024
    Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 8 institutions in 3 countries.

Khadija KhanAfrica Health Research Institute, Durban, South Africa.
Gila LustigCentre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Mallory BernsteinAfrica Health Research Institute, Durban, South Africa.
Derseree ArcharyCentre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Sandile CeleAfrica Health Research Institute, Durban, South Africa.
Farina KarimAfrica Health Research Institute, Durban, South Africa.
Muneerah SmithDepartment of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Yashica GangaAfrica Health Research Institute, Durban, South Africa.
Zesuliwe JuleAfrica Health Research Institute, Durban, South Africa.
Kajal ReedoyAfrica Health Research Institute, Durban, South Africa.
Yoliswa MiyaAfrica Health Research Institute, Durban, South Africa.
Ntombifuthi MthabelaAfrica Health Research Institute, Durban, South Africa.
Nombulelo P MagulaDepartment of Medicine, King Edward VIII Hospital and University of KwaZulu Natal, Durban, South Africa.
Richard LessellsSchool of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
Tulio de OliveiraSchool of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
Bernadett I GosnellDepartment of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa.
Salim Abdool KarimCentre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Nigel GarrettCentre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Willem HanekomAfrica Health Research Institute, Durban, South Africa.
Linda-Gail BekkerInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Glenda GraySouth African Medical Research Council, Cape Town, South Africa.
Jonathan M BlackburnDepartment of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Mahomed-Yunus S MoosaDepartment of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa.
Alex SigalAfrica Health Research Institute, Durban, South Africa.ORCID 0000-0001-8571-2004
COMMIT-KZN Team
Africa Health Research Institute · ZACentre for the AIDS Programme of Research in South Africa · ZAUniversity of Cape Town · ZAUniversity of KwaZulu-Natal · ZADesmond Tutu HIV Foundation · ZAKing Edward VIII Hospital · ZASouth African Medical Research Council · ZAUniversity of Washington · US

Funding

Identification of the HIV Reservoir in Lymph Nodes Using Single Cell RNA-SeqR01AI138546 · NIAID · KWAZULU-NATAL RESEARCH INSTITUTE TB-HIV · PI SIGAL, ALEXANDER · 2018 to 2022
$721k
NIAID NIH HHS R01 AI138546
6 · The paper itself

Abstract

backgroundPeople living with HIV (PLWH) have been reported to have a higher risk of more severe COVID-19 disease and death. We assessed the ability of the Ad26.CoV2.S vaccine to elicit neutralizing activity against the Delta variant in PLWH relative to HIV-negative individuals. We also examined effects of HIV status and suppression on Delta neutralization response in SARS-CoV-2-infected unvaccinated participants.

methodsWe enrolled participants who were vaccinated through the SISONKE South African clinical trial of the Ad26.CoV2.S vaccine in healthcare workers (HCWs). PLWH in this group had well-controlled HIV infection. We also enrolled unvaccinated participants previously infected with SARS-CoV-2. Neutralization capacity was assessed by a live virus neutralization assay of the Delta variant.

resultsMost Ad26.CoV2.S vaccinated HCWs were previously infected with SARS-CoV-2. In this group, Delta variant neutralization was 9-fold higher compared with the infected-only group and 26-fold higher relative to the vaccinated-only group. No decrease in Delta variant neutralization was observed in PLWH relative to HIV-negative participants. In contrast, SARS-CoV-2-infected, unvaccinated PLWH showed 7-fold lower neutralization and a higher frequency of nonresponders, with the highest frequency of nonresponders in people with HIV viremia. Vaccinated-only participants showed low neutralization capacity.

conclusionsThe neutralization response of the Delta variant following Ad26.CoV2.S vaccination in PLWH with well-controlled HIV was not inferior to HIV-negative participants, irrespective of past SARS-CoV-2 infection. In SARS-CoV-2-infected and nonvaccinated participants, HIV infection reduced the neutralization response to SARS-CoV-2, with the strongest reduction in HIV viremic individuals.

Indexed as

Ad26COVS1COVID-19HIV InfectionsAntibodies, NeutralizingAntibodies, ViralHIVHumansSARS-CoV-2VaccinationAd26COVS1Antibodies, NeutralizingAntibodies, ViralAd26.CoV2.S vaccinesHIV viremiaimmunogenicityneutralizationSARS-CoV-2

Identifiers

PMID34893824
PMCPMC8689810
OpenAlexW4205457067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.